RU-27849, also known as 4,ñ-methylenetryptamine (4,ñ-methylene-T), is a serotonin receptor modulator. It can be regarded as a conformationally restricted tricyclic derivative of tryptamine or a structurally simplified derivative of LSD. This molecule was developed during structureâÂÂactivity relationship (SAR) studies of LSD.
It shows affinity for serotonin receptors, including for the serotonin 5-HT<sub>1</sub>, 5-HT<sub>1A</sub>, and 5-HT<sub>2</sub> receptors ( = 267âÂÂ520nM, 325âÂÂ326nM, and 1,964âÂÂ2,900nM, respectively). RU-27849's affinities for serotonin receptors are similar to but lower than those of tryptamine and dimethyltryptamine (DMT). It shows very weak affinity for dopamine receptors and weak associated activity.
The 6-methoxy derivative of RU-27849, which is to RU-27849 as 5-methoxytryptamine is to tryptamine, appears to have much higher affinity for serotonin receptors than RU-27849 itself ( â 50nM). A number of other derivatives also exist, including FHATHBIN (6-hydroxy), RU-28306 (N,N-dimethyl), RU-28251 (N,N-dipropyl), Bay R 1531 (LY-197206; 6-methoxy-N,N-dipropyl), LY-293284 ((4R)-6-acetyl-N,N-dipropyl), and LY-178210 (6-carboxamido-N,N-dipropyl), as well as NDTDI, among others.
RU-27849 was first described in the scientific literature by 1981.